Clinical trials
Metastatic Lung Cancer clinical trials
Below are recruiting metastatic lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT05344209RecruitingPhase 2
Pembrolizumab plus or minus vaccine for advanced lung cancer
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Drammen, AkershusAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT05332925Recruiting
Tumor samples grown in dishes to predict immunotherapy response
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Fairway, KansasAges 18–110 - NCT06230666Recruiting
Comparing two SBRT methods for multiple cancer spots
This trial compares two ways of giving high-precision radiation (SBRT) to multiple cancer spots outside the brain. It aims to see if using one radiation plan for all spots is as effective and safe as using separate plans.
ZurichAges 18 years+ - NCT06399926Recruiting
Pemetrexed via Ommaya for lung cancer in brain lining
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
Changsha, HunanAges 18 years+ - NCT06440954RecruitingPhase 2
Pemetrexed injected into spinal fluid for lung cancer that spread to brain lining
This study tests a treatment called intrathecal pemetrexed, which is chemotherapy given directly into the fluid around your brain and spine. It's for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord after targeted therapy stopped working.
Changsha, HunanAges 18 years+ - NCT07830342RecruitingPhase 1
Study of tumor-infiltrating lymphocyte therapy for advanced non-small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
ShanghaiAges 18–75 - NCT06485544RecruitingPhase 2
Immunotherapy before surgery for small cell lung cancer
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Xi'an, ShannxiAges 18–75 - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT07759856RecruitingPhase 2
Natural killer cells plus immunotherapy for small cell lung cancer
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06348927RecruitingPhase 2
Sunvozertinib plus anlotinib for first-line EGFR-mutant lung cancer
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
Changsha, HunanAges 18 years+ - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT06355609RecruitingPhase 2
Targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
Changsha, HunanAges 18 years+ - NCT07697586RecruitingPhase 2
Two new drugs for advanced lung cancer without EGFR or ALK
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
Jilin CityAges 18–75 - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07658196RecruitingPhase 1
TLR9 immunotherapy for stomach or appendix cancer spreading in the abdomen
This trial tests an experimental immunotherapy that targets a protein called TLR9 to help your immune system fight cancer cells that have spread into the lining of your abdomen (peritoneal carcinomatosis). It's for people with colorectal or appendix cancer that has spread this way and may also have some limited spread to the liver or lungs.
Providence, Rhode IslandAges 18 years+ - NCT07647094RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic lung cancer?
- Yes. Clin2 currently lists 1,188 recruiting metastatic lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.